Late recurrence, high-risk features, and treatment failure can signal midlife night sweats aren’t menopause, according to Cheryl Cox Kinney, MD.
|Videos|March 31, 2021
LARC in the time of COVID and telehealth: Part 1
This video interview features Rachael Phelps, MD, Medical Director at Planned Parenthood of Central and Western New York, and of the Rochester LARC Initiative; and Amber Truehart, MD, Assistant Professor of Obstetrics and Gynecology, Section of Family Planning and Contraceptive Research at the University of Chicago.
Advertisement
Advertisement
Related to this article
Menopausal brain fog is common, and hormone therapy has neutral cognitive effects, according to Pauline M. Maki, PhD.
Distress, not low libido alone, defines HSDD, which requires a biopsychosocial evaluation, according to Holly N. Thomas, MD, MS.
Open-ended questions help ob-gyns untangle GSM and low desire and build adherence-focused treatment plans, according to Sheryl Kingsberg, PhD.
The investigational Evident test requires 3 tumor markers on the same extracellular vesicle to flag early-stage ovarian cancer.
Real-world fezolinetant (Veozah) sleep data help ob-gyns counsel patients hesitant about hormone therapy, according to Marla Shapiro, CM, MDCM.
Cultural upbringing gives context to sexual dysfunction but does not make the diagnosis, according to Sameena Rahman, MD, FACOG.
Advertisement
Advertisement
Trending on Contemporary OB/GYN
1
Before Pregnancy Begins: Why the Timing of Carrier Screening Matters
2
Brain fog at menopause: Separating normal change from dementia
3
Neurokinin receptor antagonists improve menopausal sleep disturbance
4
Stephanie Faubion, MD, on the first menopause therapy discussion
5